PBAC moves to restrict subsidised use of ezetimibe to ‘high risk’ patients

Many patients may no longer have the option to be reimbursed for taking the lipid lowering drug ezetimibe to achieve lower LDL-C targets if the PBS accepts recommendations to clamp down on costly overprescribing. The number of patients prescribed ezetimibe outside of PBS restriction criteria could be as high 53% the Pharmaceutical Benefits Advisory Committee ...

Already a member?

Login to keep reading.

© 2021 the limbic